<DOC>
	<DOC>NCT00154089</DOC>
	<brief_summary>The primary objective of this study is to determine pilot safety and efficacy data for a topical formulation of EM-1421 applied to the cervix of patients with CIN 1, 2, or 3.</brief_summary>
	<brief_title>A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia</brief_title>
	<detailed_description>This was an open-label, pilot Phase I/II dose evaluation and pharmacokinetic evaluation study to compare the safety and efficacy of terameprocol (45mg or 90mg/application)administered once per week for 3 weeks to the cervix uteri in patients with biopsy-proven CIN. Patients who met eligibility criteria visited the clinic weekly for terameprocol application. Patients kept a daily diary card record of genitourinary symptoms.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma in Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Masoprocol</mesh_term>
	<criteria>18 years of age or older Negative pregnancy test Biopsy confirmed CIN 1, 2, or 3 Pregnancy or breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>cervical intraepithelial neoplasia</keyword>
	<keyword>CIN</keyword>
	<keyword>HPV</keyword>
</DOC>